Navigation Links
Paradigm shift in Alzheimers's research: new treatments

Alzheimers disease (AD) is a progressive neurodegenerative disorder characterized by extensive neuronal degeneration and the development of neuritic amyloid plaques and neurofibrillary tangles. Neuronal and synaptic losses in AD are correlated with dementia and occur in specific brain areas involved in memory processing.

Long-standing evidence shows that progressive cerebral deposition of A" plays a seminal role in the pathogenesis of AD. There is great interest, therefore, in understanding the proteolytic processing of APP, the precursor of A", and its proteases responsible for generating A". Ragged peptides with a major species beginning with phenylalanine at position 4 of Ab have been reported already in 1985 by Masters et al.1.

In 1992, Mori et al. first described the presence of A"N3(pE) using mass spectrometry of purified A" protein from AD brains, which explains the difficulties in sequencing the amino-terminus2. They reported that only 10-15% of the total A" isolated by this method begins at position 3 with A"N3(pE). Later it became clear that A"N3(pE) represents a dominant fraction of A" peptides in AD and Downs syndrome brain3-15.

N-terminal deletions in general enhance aggregation of "-amyloid peptides in vitro16. A"N3(pE) has a higher aggregation propensity17,18, and stability19, and shows an increased toxicity compared to full-length A"20. In AD only a small proportion of A" starts at position 1 with L-aspartate in plaques (~10%), and this fraction is higher in vascular amyloid (~65%). In plaques, ~50% of the amyloid starts at position 3 in the form of A"N3(pE), whereas in the vascular amyloid, this form accounts for only 11%5.

A comparison between amyloid peptides of cognitively normal elderly people and AD patients showed that soluble amyloid aggregates are different between these groups. In AD the major A" species started with N3(pE) and ended at the C-terminus at position 4211.

Neuropathological features

To identify the molecular mechanisms that lead to AD-typical neuropathological hallmarks transgenic mouse models proved to be a valuable tool. We have been characterizing the APP/PS1KI mouse model that closely mimics the development of AD related neuropathological features including a significant neuronal loss in the hippocampus, a structure involved in learning and memory processes21. Specific neurodegeneration in the hippocampal CA1 subfield and entorhinal cortex is an early event in the AD pathology that correlates directly with the severity of the disease22. As in post-mortem AD brain, it has been demonstrated that the APP/PS1KI mouse model harbours abundant N-modified A"42 including A"N3(pE). We therefore used this model to study a possible link between accumulation of A"N3(pE) and down-stream AD-typical pathological events. This transgenic mouse model carries M233T/L235P knocked-in mutations in presenilin-1 and overexpresses mutated human "-amyloid precursor protein. A"x-42 is the major form of A" species present in this model with progressive development of a complex pattern of N-truncated variants and dimers, similar to those observed in AD brain.

At the age of six months an age-dependent significant reduced ability to perform working memory and motoric tasks is seen in these mice. The APP/PS1KI mice were smaller and showed development of a thoralumbar kyphosis, together with reduced body weight, and axonal degeneration in brain and spinal cord23. At six months of age already a 33% CA1 neuron loss in the hippocampus, together with a drastic reduction of long-term potentiation was observed24.

CA1 neuron loss in these mice is likely to contribute to the working memory deficits and complete loss of synaptic plasticity (long-term potentiation) after stimulation of the Schaffer collaterals. Intraneuronal A" and peptides beginning with aspartate at position 1, and pyro-glutamate at position 3 were detected as early as two months of age. Accumulation increased significantly at the age of six months. Of all A" peptides studied, the peptide that starts with pyro-glutamate (A"N3(pE)) at position 3 showed the highest increase in accumulation in neurons by 435%.

At 10 months of age, an extensive neuronal loss (>50%) is present in the CA1/2 hippocampal pyramidal cell layer that correlates with strong accumulation of intraneuronal A" and thioflavine-S-positive intracellular material but not with extracellular A" deposits. A strong reactive astrogliosis develops together with the neuronal loss.

Cholinergic deficits

Moreover, we have studied the neuron loss in different cholinergic nuclei and found that cholinergic neurons degenerate as a function of intraneuronal A"X-42 accumulation. This finding may explain cholinergic deficits in AD patients and indicates that cholinergic dysfunction is a down-stream event in AD pathology.

In addition, complete loss of neurogenesis in the dentate gyrus in APP/PS1KI mice points to a degenerative mechanism, which is independent from intracellular A" aggregation. No intracellular A" was detected in these neurons. The reduced number of dentate gyrus neurons (-30% at six months of age) may be at least partly a function of loss of neurogenesis.

Clinical implications

  • Overall, this mouse model develops a robust neuronal dysfunction and degeneration, which triggers AD-typical changes on different levels including synaptic plasticity and working memory.

  • The neuron loss in different brain areas mostly follows the pattern of intraneuronal A"X-42 accumulation.

  • From these observations we conclude that intraneuronal A"X-42 accumulation is the major neurotoxic factor in AD etiology.

  • Of special interest is that pyro-glutamate-A"42 is the variant, which aggregates fastest in degenerating neurons. This is likely due to its enhanced stability and propensity to aggregate.

  • Therefore, this peptide most likely seems to be responsible for the observed neuronal toxicity.

The prevention of pyro-glutamate A" aggregation is therefore an important mechanism and therapeutic target.


Contact: Thomas A. Bayer
European College of Neuropsychopharmacology

Related biology news :

1. Navigating the brain for sense of direction as paradigm for higher cognitive functions
2. Protein splicing upsets the DNA colinearity paradigm
3. Shift of weather patterns necessitates rethinking of reforestation methods
4. After a time-shift, mixed signals from the circadian clock
5. Scripps scientists find potential for catastrophic shifts in Pacific ecosystems
6. Radio-tracking associated with dramatic shift in water vole sex ratio
7. Neandertal femur suggests competition with hyenas and a shift in landscape use
8. Shifty-eyed Monkeys Offer Window Into Brains Social Reflexes
9. Molecular research suggest shift needed in how some drugs are created
10. Great (taste) expectations: Study shows brain anticipates taste, shifts gears
11. Evolutionary shifts in olfactory sensitivities in fruit flies
Post Your Comments:
(Date:11/12/2015)... CAMBRIDGE, Mass. , Nov. 12, 2015 /PRNewswire/ ... Broad Institute of MIT and Harvard for use ... chemical discovery information management tools. The partnership will ... share both biological and chemical research information internally ... tools will be used for managing the Institute,s ...
(Date:11/9/2015)... 09, 2015 ... the "Global Law Enforcement Biometrics Market ... --> ) has announced the ... Biometrics Market 2015-2019" report to their ... ( ) has announced the addition ...
(Date:10/29/2015)... Calif. , Oct. 29, 2015  The J. ... new report titled, "DNA Synthesis and Biosecurity: Lessons Learned ... the Department of Health and Human Services guidance for ... in 2010. --> ... it also has the potential to pose unique biosecurity ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... ... November 24, 2015 , ... The Academy of Model Aeronautics (AMA), led ... also known as Multirotor Grand Prix, to represent the First–Person View (FPV) racing community. ... members have embraced this type of racing and several new model aviation pilots have ...
(Date:11/24/2015)... Technologies Ltd. (OTCQB: TIKRF) today announced that its Annual General Meeting of ... Israel time, at the law offices of Goldfarb ... Floor, Tel Aviv, Israel . ... Tamir to the Board of Directors; , election of ... of an amendment to certain terms of options granted to our Chief ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... are paramount. Insertion points for in-line sensors can represent a weak spot where ... InTrac 781/784 series of retractable sensor housings , which are designed to tolerate ...
(Date:11/24/2015)... , Nov. 24, 2015 /CNW Telbec/ - ProMetic Life ... announced today that Mr. Pierre Laurin , President and ... presentation at the upcoming Piper Jaffray 27 th Annual ... Hotel, on December 1-2, 2015. st , ... for one-on-one meetings throughout the day. The presentation will be ...
Breaking Biology Technology: